1. At a Glance – The Painkiller That’s Nursing Its Own Pain
IOL Chemicals & Pharmaceuticals Ltd is currently trading at ₹74.7 with a market cap of ₹2,194 crore. In the last three months, the stock has fallen 21.9% — which is ironic because this company literally manufactures painkillers.
Latest quarterly sales came in at ₹580 crore, up 10.9% YoY, while PAT jumped 40.9% to ₹29 crore. OPM stands at 10.8% for TTM and ROCE at 8.86%. Stock P/E is 17.6 compared to an industry P/E of 28.5. Debt? A modest ₹159 crore. Promoters hold 52.6% with zero pledge.
Sounds decent, right?
But zoom out: 5-year sales growth is just 1.88%. 3-year profit growth is negative. ROE over 3 years is only 8%.
So what are we looking at — a cyclical rebound in APIs or a structurally slowing business trying to diversify away from Ibuprofen dependence?
Let’s open the strip pack and read the fine print.
2. Introduction – The Ibuprofen Emperor With a Margin Headache
If you have ever popped an Ibuprofen tablet for fever or muscle pain, there is a 35% chance the raw ingredient came from IOL. Yes. This Punjab-based company controls roughly one-third of the global Ibuprofen supply. That’s not small. That’s not mid-sized. That’s “global muscle”.
But here’s the twist.
Despite being the world’s largest Ibuprofen producer, the stock has underperformed over 5 years (-10.7% return). Sales growth has been stagnant. Margins compressed post FY21 peak. ROE cooled down from 15%+ to 6% last year.
Classic commodity cycle.
API pricing is like onion pricing — one year tears of joy, next year tears of pain.
So management is trying to diversify. Non-Ibuprofen APIs now form 34% of API revenue in H1 FY25, up from 14% in FY20. Export share rising. China approvals coming in. EDQM certificates stacking up.
Is this strategic evolution or just survival mode?
Let’s understand what this business really does.
3. Business Model – WTF Do They Even Do?
Imagine a factory that makes the raw ingredients for medicines before brands package them.
That’s IOL.
Two segments:
1️ Pharmaceuticals (57% of H1 FY25 revenue)
They manufacture APIs like:
- Ibuprofen
- Metformin
- Paracetamol
- Clopidogrel
- Pantoprazole
- Lamotrigine
Capacity highlights:
- Ibuprofen: 12,000 MTPA
- Paracetamol: 3,600 MTPA
- Metformin: 7,200 MTPA
They hold 15 USDMFs and 17 CEPs. Recently received CEP approvals for Minoxidil, Sitagliptin, Pantoprazole, and Quetiapine in FY25–26.
Translation: They are trying to move up regulatory credibility ladder.
2️ Chemicals (43%)
They manufacture:
- Ethyl Acetate (1,00,000 TPA)
- Iso Butyl Benzene
- Mono Chloro Acetic Acid
- Acetic Anhydride
Chemicals are cyclical. When realizations fall, margins collapse.
Between FY22–FY24, chemical segment revenue fell 27%.
So pharma is the stability play, chemicals the volatility play.
